Abstract
It has become increasingly clear that anti-tuberculosis regimens need optimization. Information gained using pharmacokinetics/ pharmacodynamics (PK/PD) methods in hollow fiber and animal model studies, in conjunction with Monte Carlo simulations, can be used to achieve this goal. PK/PD models of anti-tuberculosis drugs in hollow fibers, mice and guinea pigs have been remarkably concordant. Using exposures derived in these models it has been shown that the standard doses of pyrazinamide, rifampin, and ethambutol should be increased for a better efficacy, while doses of isoniazid need to be individualized. In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824.
Keywords: Mycobacterium tuberculosis, PK-PD, models, dosing schedule, dose optimization, bacteria, monotherapy, isoniazid, Fluoroquinolones, meningitis
Current Pharmaceutical Design
Title: In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Volume: 17 Issue: 27
Author(s): Shashikant Srivastava and Tawanda Gumbo
Affiliation:
Keywords: Mycobacterium tuberculosis, PK-PD, models, dosing schedule, dose optimization, bacteria, monotherapy, isoniazid, Fluoroquinolones, meningitis
Abstract: It has become increasingly clear that anti-tuberculosis regimens need optimization. Information gained using pharmacokinetics/ pharmacodynamics (PK/PD) methods in hollow fiber and animal model studies, in conjunction with Monte Carlo simulations, can be used to achieve this goal. PK/PD models of anti-tuberculosis drugs in hollow fibers, mice and guinea pigs have been remarkably concordant. Using exposures derived in these models it has been shown that the standard doses of pyrazinamide, rifampin, and ethambutol should be increased for a better efficacy, while doses of isoniazid need to be individualized. In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824.
Export Options
About this article
Cite this article as:
Srivastava Shashikant and Gumbo Tawanda, In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470192
DOI https://dx.doi.org/10.2174/138161211797470192 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Targeting of the Inflamed Intestinal Barrier
Current Pharmaceutical Design Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Current Drug Safety Lactoferricin Derived From Milk Protein Lactoferrin
Current Pharmaceutical Design Current Applications of the Sonogashira Reaction in the Synthesis of Heterocyclic Compounds: An Update
Current Organic Chemistry Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Molecular Insights into the Interaction of Ursolic Acid and Cucurbitacin from Colocynth with Therapeutic Targets of <i>Mycobacterium tuberculosis</i>
Letters in Drug Design & Discovery Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry The Role of Infection in Carotid Plaque Pathogenesis and Stability: The Clinical Evidence
Current Vascular Pharmacology miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Optimizing Glycosylation Reaction Selectivities by Protecting Group Manipulation
Current Bioactive Compounds Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening DNA-Minor Groove Binding Agents as Anti-Tubercular Probes. Old Tools for a New Challenge?
Anti-Infective Agents The Role of Essential Oils and the Biological Detoxification in the Prevention of Aflatoxin Borne Diseases
Current Topics in Medicinal Chemistry Hepatitis C Viruss Immune Evasion Strategies
Current Immunology Reviews (Discontinued) Toll-Like Receptors, Cytokines and the Immunotherapeutics of Asthma
Current Pharmaceutical Design Diffuse Large B-Cell Lymphoma with Involvement of the Chest Wall
Current Respiratory Medicine Reviews The Effect of Protein Restriction in the In Vitro Metabolism of Albendazole in Rats
Drug Metabolism Letters GRAPHICAL ABSTRACTS
Letters in Drug Design & Discovery